





**Supplementary Fig. 1** (**A**) Disease-free survival of HCC patients with clear cell carcinoma who had the indicated tumor diameters. (**B**) Disease-free survival of HCC patients with clear cell carcinoma who had satellite nodules or not. (**C**) Disease-free survival of HCC patients with clear cell carcinoma whose alpha-fetoprotein levels were ≤20 or >20 ng/mL. (**D**) Disease-free survival of HCC patients with clear cell carcinoma who had PVTT or not. (**E**) Disease-free survival of HCC patients with clear cell carcinoma who had cirrhosis or not.

 

 

**Supplementary Fig. 2** (**A**) Comparison of the overall survival curves between Ki-67≤30% and Ki-67＞30%. (**B**) Comparison of the overall survival curves between tumor diameter ≤5 or >5 cm. (**C**) Comparison of the overall survival curves for patents with or without satellite nodules. (**D**) Comparison of the overall survival curves for patients with or without a tumor capsule.

 

**Supplementary Fig. 3** (**A**) Validation of the nomogram’s prediction of 1-year disease-free survival (DFS) of HCC patients with clear cell carcinoma. (**B**) The calibration curve for predicting 3-year DFS of HCC patients with clear cell carcinoma. (**C**) The calibration curve for predicting 5-year DFS of HCC patients with clear cell carcinoma.

 



**Supplementary Fig. 4** (**A**) Validation of the nomogram’s prediction of 1-year overall survival (OS) of HCC patients with clear cell carcinoma. (**B**) The calibration curve for predicting 3-year OS of HCC patients with clear cell carcinoma. (**C**) The calibration curve for predicting 5-year OS of HCC patients with clear cell carcinoma.

**Supplementary Table 1** Clinicopathologic characteristics of hepatocellular carcinoma patients in our study

|  |  |  |  |
| --- | --- | --- | --- |
| Characteristic | with clear cell carcinoma（n=239） | without clear cell carcinoma (n=231) | *P*-value |
| Age (years) | 52.4±11.4 | 49.1±11.2 | 0.001 |
| Sex MaleFemale | 207 (87)32 (13) | 180 (78)51 (22) | 0.014 |
| AFP (ng/mL)≤20＞20 | 98 (41)141 (59) | 54 (23)177 (77) | ＜0.001 |
| CirrhosisPresenceAbsence | 35 (15)204 (85) | 47 (20)184 (80) | 0.103 |
| HBsAg Positive  Negative  | 198 (83)41 (17) | 206 (89)25 (11) | 0.048 |
| Child-Pugh class A B | 226 (95)13 (5) | 225 (97)6 (3) | 0.118 |
| Tumor number Single Multiple  | 191 (80)48 (20) | 168 (73)63 (27) | 0.067 |
| Tumor size (cm)≤5＞5 | 89 (37)150 (63) | 47 (20)184 (80) | ＜0.001 |
| Satellite nodulesPresenceAbsence | 32 (13)207 (87) | 53 (23)178 (77) | 0.007 |
| MVIPresenceAbsence | 80(33)159(67) | 121(52)110(48) | ＜0.001 |
| Capsule formationPresenceAbsence | 124 (52)115 (48) | 117 (51)114 (49) | 0.789 |
| PVTTPresent Absent | 23 (10)216 (90) | 44 (19)187 (81) | 0.003 |
| TransfusionYes No | 54 (23)185 (77) | 78 (34)153 (66) | 0.007 |
| BCLCABC | 17 1 (71)42 (18)26 (11) | 144 (62)44 (19)43 (19) | 0.040 |
| Edmondson gradeⅠ-ⅡⅢ-Ⅳ | 129 (54)110 (46) | 114 (49)117 (51) | 0.316 |
| Ki-67（%） ≤30 ＞30 | 149 (62) 90 (38)  | 116 (50) 115 (50) | 0.008 |

Values are n (%) unless otherwise noted.

Abbreviations: AFP, alpha-fetoprotein level; BCLC, Barcelona Clinic Liver Cancer; HBsAg, serum hepatitis B surface antigen; MVI, microvascular invasion; PVTT, portal vein tumor thrombosis.